Methyl 5-(trifluoromethyl)-2-(3-((6-(trifluoromethyl)pyridin-2-yl)oxy)azetidin-1-yl)nicotinate → 5-(Trifluoromethyl)-2-(3-((6-(trifluoromethyl)pyridin-2-yl)oxy)azetidin-1-yl)nicotinic acid
반응식
[F:1][C:2]([F:29])([F:28])[C:3]1[CH:4]=[N:5][C:6]([N:13]2[CH2:16][CH:15]([O:17][C:18]3[CH:23]=[CH:22][CH:21]=[C:20]([C:24]([F:27])([F:26])[F:25])[N:19]=3)[CH2:14]2)=[C:7]([CH:12]=1)[C:8]([O:10]C)=[O:9].OC1C=CC=C(C(F)(F)F)N=1>>[F:29][C:2]([F:1])([F:28])[C:3]1[CH:4]=[N:5][C:6]([N:13]2[CH2:16][CH:15]([O:17][C:18]3[CH:23]=[CH:22][CH:21]=[C:20]([C:24]([F:25])([F:26])[F:27])[N:19]=3)[CH2:14]2)=[C:7]([CH:12]=1)[C:8]([OH:10])=[O:9]참가 물질
3
실험 절차
The title compound (D130) (77 mg) was prepared according to the experimental procedure described in Description 129 starting methyl 5-(trifluoromethyl)-2-(3-((6-(trifluoromethyl)pyridin-2-yl)oxy)azetidin-1-yl)nicotinate (D89) (80 mg, 0.19 mmol) and 2-Hydroxy-6-(trifluoromethyl)pyridine (55.12 mg, 0.34 mmol).
출처 및 근거
- ORD 기록
- ord-e327a5667eb046d181940d183ad39fb3